Cargando…
Oncolytic Immunotherapy: Where Are We Clinically?
Following a century of preclinical and clinical work, oncolytic viruses are now proving themselves in randomized phase 3 trials. Interestingly, human data indicates that these agents have potent immunostimulatory activity, raising the possibility that the key consequence of oncolysis might be induct...
Autor principal: | Hemminki, Akseli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914551/ https://www.ncbi.nlm.nih.gov/pubmed/24551478 http://dx.doi.org/10.1155/2014/862925 |
Ejemplares similares
-
Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020) -
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
por: Turnbull, Samantha, et al.
Publicado: (2015) -
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015) -
Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022) -
Portrait of a Leader in Immunotherapeutics: Oncolytic viruses for treatment of cancer
por: Hemminki, Akseli
Publicado: (2012)